The molecular interaction of a copper chelate with human P-glycoprotein

Molecular and Cellular Biochemistry

Volumn 364, Issue 1-2, 2012, Pages 309-320

  Ghosh, Ruma Dey ^a   Chakraborty, Paramita ^a   Banerjee, Kaushik ^a   Adhikary, Arghya ^b   Sarkar, Avijit ^c   Chatterjee, Mitali ^c   Das, Tanya ^b   Choudhuri, Soumitra Kumar ^a  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

^b BOSE INSTITUTE   (India)

^c INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

125I IAAP labeling; Copper (II) N (2 hydroxyacetophenone) glycinate (CuNG); Multidrug resistance; NIH MDR1 G185 cells; P glycoprotein; Uic2 antibody

Indexed keywords

ADENOSINE TRIPHOSPHATASE; COMPLEMENTARY DNA; COPPER COMPLEX; COPPER N (2 HYDROXYACETOPHENONE)GLYCINATE; DOXORUBICIN; ESTROGEN; GLYCOPROTEIN P; IODINE 125; IODOARYLAZIDOPRAZOSIN I 125; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY UIC2; MULTIDRUG RESISTANCE PROTEIN 1; PROGESTERONE; SCHIFF BASE; UNCLASSIFIED DRUG; VERAPAMIL; VINBLASTINE;

ANIMAL CELL; ANTIGEN BINDING; ARTICLE; BINDING SITE; CELL ASSAY; CHEMICAL STRUCTURE; CONCENTRATION RESPONSE; DOWN REGULATION; DRUG ACCUMULATION; DRUG BINDING; DRUG DESIGN; DRUG TRANSPORT; ENZYME ACTIVITY; MOLECULAR INTERACTION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PHOTOAFFINITY LABELING; PROTEIN EXPRESSION; PROTEIN INTERACTION;

ADENOSINE TRIPHOSPHATASES; ANIMALS; CELL LINE; CHELATING AGENTS; COPPER; DOXORUBICIN; FIBROBLASTS; GLYCINE; HUMANS; MICE; ORGANOMETALLIC COMPOUNDS; P-GLYCOPROTEIN;

EID: 84863989257     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-012-1232-z     Document Type: Article

References (38)

1. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM (1999) Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361-398 (Pubitemid 29222564)
2. Brost P, Elferink RO (2002) Mammalian ABC transporters in health and disease. Annu Rev Biochem 71:537-592
3. Krishna R, Mayer LD (2000) Multidrug resistance (MDR) in cancer mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 11:265-283
4. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219-234 (Pubitemid 43336035)
5. Boote DJ, Dennis IF, Twentyman PR, Osborne RJ, Laburte C, Hensel S (1996) Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 14:610-618 (Pubitemid 26051028)
6. Kruijtzer CM, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC (2002) Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 20:2943-2950 (Pubitemid 34728888)
7. Sandler A, Gordon M, De Alwis DP, Pouliquen I, Green L, Marder P (2004) A phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. Clin Cancer Res 10:3265-3272 (Pubitemid 38685430)
8. Stewart A, Steiner J, Mellows G, Laguda B, Norris D, Bevan P (2000) Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. Clin Cancer Res 6:4186-4191
9. Tolcher AW, Cowan KH, Solomon D, Ognibene F, Goldspiel B, Chang R (1996) Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. J Clin Oncol 14:1173-1184 (Pubitemid 26105524)
10. Tisato F, Marzano C, Porchia M, Pellei M, Santini C (2009) Copper in diseases and treatments, and copper-based anticancer strategies. Medcinal Res Rev 1:42-52
11. Majumder S, Panda GS, Choudhuri SK (2003) Synthesis, characterization and biological properties of a novel copper complex. Eur J Med Chem 38:893-898 (Pubitemid 37311403)
12. Majumder S, Dutta P, Mookerjee A, Choudhuri SK (2006) The role of a novel copper complex in overcoming doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo. Chem Biol Interact 159:90-103 (Pubitemid 43042617)
13. Chatterjee S, Mookerjee A, Mookerjee Basu J, Chakroborty P, Ganguly A, Adhikary A, Mukhopadhyay D, Ganguli S, Banerjee R, Mohammad A, Biswas J, Das PK, Sa G, Chatterjee M, Das T, Choudhuri SK (2009) A novel copper chelate modulates tumor associated macrophages to promote anti-tumor response of T cells. PLoS One 4(9):e7048
14. Mookerjee A, Mookerjee Basu J, Dutta P, Majumder S, Bhattacharyya S, Biswas J, Pal S, Mukherjee P, Raha S, Baral RN, Das T, Efferth T, Sa G, Roy S, Choudhuri SK (2006) Overcoming drug-resistant cancer by a newly developed copper chelate through host-protective cytokine-mediated apoptosis. Clin Cancer Res 12:4339-4349
15. Mookerjee A, Basu JM, Majumder S, Chatterjee S, Panda GS, Dutta P, Pal S, Mukherjee P, Efferth T, Roy S, Choudhuri SK (2006) A novel copper complex induces ROS generation in doxorubicin resistant Ehrlich ascitis carcinoma cells and increases activity of antioxidant enzymes in vital organs in vivo. BMC Cancer 6:267-277
16. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL, Chang G (2009) Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323:1718-1722
17. Choudhuri SK (2005) Indian patent entitled "non toxic anti cancer drug resistance modifying agent and an anticancer kit including the same." Classification no. A61K 31/00. Bigpatents India 1:1-2
18. Currier SJ, Kane SE, Willingham MC, Cardarelli CO, Pastan I, Gottesman MM (1992) Identification of residues in the first cytoplasmic loop of P-glycoprotein involved in the function of chimeric human MDR1-MDR2 transporters. J Biol Chem 267:25153-25159
19. Kuffei MJ, Ames MM (1995) Comparative resistance of idarubicin, doxorubicin and their C-13 alcohol metaboUtes in human MDR1 transfected NIH-3T3 Cells. Cancer Chemother Pharmacol 36:223-226
20. Wan CK, Zhu GY, Shen XL, Chattopadhyay A, Dey S, Fong WF (2006) Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in GHepG2-DR cells. Biochem Pharmacol 72:824-837 (Pubitemid 44301053)
21. Dey S, Ramachandra M, Pastan I, Gottesman MM, Ambudkar SV (1997) Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad Sci USA 94:10594-10599
22. Bradford MM (1976) A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
23. Maki N, Hafkemeyer P, Dey S (2003) Allosteric modulation of human P-glycoprotein Inhibition of transport by preventing substrate translocation and dissociation. J Biol Chem 278:18132-18139 (Pubitemid 36799427)
24. Sarkadi B, Price EM, Boucher RC, German UA, Scarborough GA (1992) Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug stimulated membrane ATPase. J Biol Chem 267:4854-4858
25. Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R (2000) Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 58:624-632
26. Sauna ZE, Smith MM, Muller M, Ambudkar SV (2001) The mechanism of action of multidrug resistance-linked p-glycoprotein. J Bioenerg Biomembr 33:481-491 (Pubitemid 34052574)
27. Ambudkar SV, Lelong IH, Zhang J, Cardarelli CO, Gottesman MM, Pastan I (1992) Partial purification and reconstitution of the human multidrug resistance pump: characterization of the drugstimulatable ATP hydrolysis. Proc Natl Acad Sci USA 89:8472-8476
28. Garrigues A, Nugier J, Orlowski S, Ezan E (2002) A highthroughput screening microplate test for the interaction of drugs with P-glycoprotein. Anal Biochem 305:106-114 (Pubitemid 34575830)
29. Pascaud C, Garrigos M, Orlowski S (1996) Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents. Biochem J 333:351-358 (Pubitemid 28379536)
30. Sikic BI (1999) Modulation of multidrug resistance: a paradigm for translational clinical research. Oncology (Huntingt) 3:183-187
31. Sharom FJ, Yu X, Lu P, Liu P, Chu JW, Szabo K, Muller M, Hose CD, Monks A, Varadi A, Seprodi J, Sarkadi B (1999) Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems and intact cells. Biochem Pharmacol 3:571-586 (Pubitemid 29296877)
32. Anuchapreeda S, Leechanachai P, Smith M, Ambudkar SV, Limtrakul P (2002) Modulation of P-glycoprotein expression and function by curcumin in multidrug resistant human KB cells. Biochem Pharmacol 64:573-582
33. Wartenberg M, Ling FC, Schallenberg M, Baumer AT, Petrat K, Hescheler J, Sauer H (2001) Down-regulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroids by reactive oxygen species. J Biol Chem 276:17420-17428
34. Ludwig JA, Szakacs G, Martin SE, Chu BF (2006) Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res 66:4808-4815
35. Rappa G, Lorico A, Liu MC, Kruh GD, Cory AH, Cory JG, Sartorelli AC (1997) Overexpression of the multidrug resistance genes mdr1, mdr3, and mrp in L1210 leukemia cells resistant to inhibitors of ribonucleotide reductase. Biochem Pharmacol 54:649-655 (Pubitemid 27404624)
36. Raviv Y, Pollard HB, Bruggemann EP, Pastan I, Gottesman MM (1990) Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J Biol Chem 265:3975-3980
37. Gottesman MM, Ambudkar SV, Xia D (2009) Structure of a multidrug transporter (News and Views article). Nat Biotech 27:546-547
38. Maki N, Moitra K, Ghosh P, Dey S (2006) Allosteric modulation bypasses the requirement for ATP hydrolysis in regenerating low affinity transition state conformation of human P-glycoprotein. J Biol Chem 281:10769-10777 (Pubitemid 43855499)